A phase II, open label, multicenter study to assess the safety and efficacy of 100mg DPC 083 once daily in combination with nucleoside analogue reverse transcriptase inhibitors in HIV-1-infected subjects who are failing treatment with a non-nucleoside reverse transcriptase inhibitor-containing regimen

Trial Profile

A phase II, open label, multicenter study to assess the safety and efficacy of 100mg DPC 083 once daily in combination with nucleoside analogue reverse transcriptase inhibitors in HIV-1-infected subjects who are failing treatment with a non-nucleoside reverse transcriptase inhibitor-containing regimen

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2009

At a glance

  • Drugs DPC 083; Nucleoside reverse transcriptase inhibitors
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top